Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks with Huge Upside Potential. On May 14, Morgan Stanley raised the price target on Recursion Pharmaceuticals, Inc.

One of the world’s leading artificial intelligence companies has implored the industry to pause development on AI, because the latest models could be reaching a tipping point where they become capable ...

Recursion Pharmaceuticals (RXRX) is scheduled to report Q2 earnings on August 4, 2026. Analysts estimate EPS of $-0.24 and quarterly revenue of $12.93M. In the most recent quarter (Q1), Recursion ...

This week’s cybersecurity recap covers Firefox and Chrome bugs, EDR-killer tools, a TV botnet, an OpenBSD flaw, Android ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Anthropic warns AI could achieve recursive self-improvement by 2028, with Claude already writing over 80% of Anthropic's code. Co-founder Jack Clark puts the odds at 60%. Here's why the company is ...